

Alastair Mackay, PhD.
410.318.5022
mackay@garpresearch.com


Luminex

Buy

May 9, 2008

LMNX - \$20

Market Cap: \$740 million



Company Description:

Luminex has developed proprietary biological testing technologies used in the life sciences industry. The company's core *xMAP* technology allows simultaneous analysis of up to 100 bioassays from a single drop of fluid by reading biological tests on the surface of microscopic polystyrene beads. The technology is used in drug discovery and development, clinical diagnostics, genetic analysis, protein analysis, and biomedical research.

Operating & Financial Highlights


(\$ Millions, Adjusted for Certain Items)

	2007	2008F	2009F	2010F
Sales	75	100	139	186
Operating Income	(5)	1	18	37
Diluted Shares	34	37	40	41
EPS	(\$0.10)	\$0.03	\$0.40	\$0.80
EPS (ex. 123R)	(\$0.00)	\$0.11	\$0.50	\$0.90
P/E	n/a	680	50	25
Operating Margins	n/a	1%	13%	20%
Capital Employed	72	25	31	38
Pretax ROCE	n/a	3%	58%	99%
Pretax ROTCE	n/a	3%	58%	99%

2008 Estimated Quarterly Results

	Q1	Q2F	Q3F	Q4F
Sales	23	24	26	27
EPS	\$0.01	\$0.01	\$0.01	\$0.00

Proprietary Quintile Ranking System



LMNX scores in GARP's most attractive growth quintile and least attractive valuation quintile. GARP's non-quantitative ratings override is in effect. See disclaimer for additional information.

Summary Points

Growth:

- We estimate that Luminex will reach *pro forma* profitability in 2008
- Revenues may increase from \$75 million in 2007 to over \$180 million in 2010.
- *xMAP* is well entrenched in the research market, but molecular diagnostics sales may account for over half of sales by 2010.

Quality:

- Luminex's *xMAP* technology is the market leader in the \$800 million multiplex assay market.
- Instrument placements spur growth in recurring consumables used in research and diagnostics.
- With gross margins over 60% and modest capital requirements, we project ROCE above 50% by 2009.

Control of Risk:

- The company may pass the break-even point in 2008, producing *pro forma* earnings.
- Luminex's assay franchise is strengthened by its early mover advantage, an installed base of 5,000 instruments, a good patent position, and a solid pipeline.

Recent Developments

Luminex posted 1Q08 sales of \$23 million, a gain of 38% over the fourth quarter of 2006, and the 7th quarter of consecutive revenue increases. We estimate that organic growth was 26%, with the remaining 12% attributed to the March 2007 acquisition of LMD. 220 instruments were placed, bringing the installed base to just shy of 5,200. Gross margins (ex royalties) jumped 400 BP from the prior-year quarter to 60%, an improvement that is unlikely to be fully sustained over the year. (In calculating *pro forma* earnings, GARP includes Luminex's modest FAS-123R stock options, but excludes depreciation from operating expenses and one-time events.) On a *pro forma* basis, Luminex earned 1¢ per fully-diluted share in the quarter, compared to a gain of 2¢ for 1Q07 (prior to the full dilutive effects of the Tm acquisition). During the quarter, Luminex received 510(k) clearance for the U.S. version of the *Respiratory Virus Panel*, and immediately began sales. Fisher Healthcare will distribute the *RVP* in the U.S., while Abbott has worldwide distribution rights. Luminex expanded its partnership with Invitrogen (IVGN – Neutral) for applications in the research arena, and took a concrete step into food-safety testing by inking a collaboration with Tyson Foods. Progress continued on the planned rollout of *FlexMap 3D* late in the year.

Please refer to important disclosures in Appendix A. The information contained herein has been obtained from sources believed reliable but is not necessarily complete and accuracy is not guaranteed. Opinions do not constitute solicitation of orders.

Recommendation Rationale

Luminex is a development-stage company that we believe will become profitable in 2008, with revenues on track to double from 2007 levels by 2010. The company invented and owns the bead-based *xMAP* technology, which is the market leader in the \$800 million multiplex assay market. *xMAP* assays are used in biomedical research, drug discovery & development, protein analysis, genetic analysis, and clinical diagnostics. Luminex is the sole supplier of the reagents and readout instruments required for all *xMAP* tests. Over half of the company's revenues are recurring, consisting of sales of beads, supplies, and complete assay kits, as well as royalties from *xMAP* assays developed and sold by partners. Since switching costs are high once the bead readers are in place, we expect that recurring revenues will continue to grow briskly. The company already has an installed base of 5,000 instruments in research and clinical laboratories throughout the world. Meanwhile, competitors in assay multiplexing are years behind, giving Luminex a significant first-mover advantage. By our out-year of 2010, GARP estimates that Luminex's revenues could exceed \$180 million, more than twice 2007 sales of \$75 million. With the company's gross margins over 60% and modest capital requirements, we project a return on capital employed exceeding 50% ROCE in 2009, with that metric rising rapidly in succeeding years.

Luminex licenses *xMAP* to its partners, receiving royalty payments that average about 6.5% of the price of tests and kits. In 2007, the total end market for *xMAP* assays was about \$170 million, mostly in the research market, where scientists use Luminex reagents to design their own unique assays. In addition, bead-based methods have been making inroads into diagnostics. Thirty-six *xMAP* multiplex assays have already been approved for clinical use by the Food and Drug Administration (FDA). Most are adaptations of tests that quantitate a single protein, relying on the specific binding of antibody to antigen. However, five of the 36 are molecular diagnostics—the analysis of nucleic acids to aid the practice of medicine. GARP projects that revenue from molecular diagnostics may reach \$90 million by 2010, becoming Luminex's primary growth driver. In this regard, the company has developed labeling procedures that allow PCR-based tests of DNA and RNA sequence to be ported to beads. The *Luminex 100* and *Luminex 200* are the only multiplexing instruments with Device Master Files (DMFs) at the FDA, easing the formidable regulatory hurdles that developers of all new diagnostic test must overcome.

Operations

While Luminex is still a development-stage company, it enjoys high gross margins, employs modest capital and is on the cusp of turning profitable. In fact, the company was able to turn a modest *pro forma* profit of \$3 million on \$52 million in sales during 2006. However, Luminex acquired molecular diagnostics developer Tm Biosciences in 2007. The resulting increases in operating expenses pushed the company slightly into the red in 2007. We forecast a return to profitability in 2008, with about \$1 million of *pro forma* operating income on \$25 million of capital employed.

Luminex has developed several revenue streams, all related to the performance of "multiplexed" assays — tests that involve the simultaneous quantitation of multiple analytes. Luminex holds patents on many aspects of its *xMAP* bead production and analysis, and has developed significant process engineering knowledge as well. *xMAP* is based on the ability to perform key chemical steps on the surface of microscopic polystyrene beads. This beads-in-suspension approach is in marked contrast to having reactions take place in solution, as is the case for traditional formats. The company's sophisticated *Luminex 100* and *Luminex 200* bead-reading instruments can run assays on dozens of analytes from a single test tube, saving considerable time and labor expense. The format is suitable for diagnostic uses; 36 *xMAP* multiplex assays have already been approved for clinical use by the FDA. As of March 2008, almost 5,200 instrument systems had been placed worldwide, 870 of them in the prior 12 months. Luminex generates revenues from instrument sales, and then benefits in following years from sustained sales of consumables to the installed base. The company's gross margin reached 62% in 2007. SG&A expenses as a proportion of revenue stood at 54%, while R&D spending topped 20% of revenue. Over the next three years, rapidly rising revenues may lead to steady improvements in these margins.

While Luminex benefits from sales of consumables and royalty revenues that are generated by its partners, it acquired development-stage Tm Biosciences for \$50 million to enable the internal development of molecular diagnostic assays. Tm's FDA-cleared *Tag-It Cystic Fibrosis Kits* detect the common mutations that cause muscular dystrophy, providing an immediate foothold in one of the larger market niches. Tm also had its *Respiratory Virus Panel (RVP)* under review. In January 2008, the FDA issued a 510(k) clearance for the *RVP Panel*, which immediately went on sale. Each kit brings in about \$50 to Luminex, at gross margins well above the corporate average.

The *FlexMAP 3D* is Luminex's next-generation bead reader. Development was completed in 2007, and sales are slated to begin in 4Q08. While the instrument is backwards-compatible with all *xMAP* reagents and assays, it introduces two innovations. First, beads that are dedicated for use with *FlexMAP 3D* are dyed with three rather than two fluorophores, yielding 1,000 "addresses" (in practice, it will have a maximum plexity of 500). Second, *FlexMAP 3D*

works with the new *MagPlex* microspheres. Rather than being solid polystyrene, each *MagPlex* bead is a plastic sphere that encapsulates a fragment of magnetite, a mineral with paramagnetic qualities. This makes the beads responsive to external magnetic fields. When a test tube is placed next to a strong magnet, it will attract paramagnetic beads to the sidewall, enabling more complete rinsing. Paramagnetic particles are especially advantageous for automated procedures, and many sample-handling robots incorporate electromagnets for this purpose.

Competition

While *xMAP* is the leading format for bioassays that are performed in a multiplexed format, each component of a multi-part assay can be run on its own, with results compiled once the laboratory work is complete. In fact, this remains the most common approach for many scientific and medical procedures. This piecemeal approach is workable in the research setting, since immunoassays are versatile and don't rely on a purpose-built instrument. However, these soak up skilled technicians' time, and are vulnerable to a host of problems, such as the drift that can be caused by inaccurate hand-pipetting. A more sophisticated approach is to automate a multi-analyte assay, performing the analysis of each component sequentially and independently. This is the principle underlying immunoassay systems such as Beckman Coulter's (BEC - Neutral) *UniCell* and Abbott Laboratories' *Architect* series of clinical analyzers. Each of dozens of assays is performed on the basis of a separate "sip" from the sample tube.

The most direct competition to *xMAP* comes from the *BeadXpress* line of instruments and reagents that Illumina (ILMN - Buy) debuted in mid-2007. As with *xMAP*, a *BeadXpress* panel combines dedicated beads from many distinct assays in a single tube. While Luminex uses a mixture of two (*Luminex 100/200*) or three (*FlexMap 3D*) embedded dyes to unambiguously assign each bead to its proper address, Illumina employs a digital approach. During manufacture, all *BeadXpress* beads of a given batch are laser-imprinted with the same holographic code. At 16 bits (2^{16}), 64,000 different codes are possible. However, *BeadXpress* cannot use the flow-cytometry approach. Instead, a few hundred beads are slotted into a tray, and then scanned. The scanning laser excites the reporting fluorescent molecule at the surface of the bead under interrogation, and then decodes the embedded hologram. The profile and size of the *BeadXpress* beads and the use of a tray instead of a cytometer are disadvantages in getting high-sensitivity data from immunoassays. While Illumina sold more than 100 instruments in 2007, its installed base is far smaller than that of Luminex. At \$80,000, the *BeadXpress* is about double the cost of a *Luminex 200*. While Illumina is a formidable competitor, GARP believes that *BeadXpress'* modest installed base, the small number of available off-the-shelf assays, and concerns about signal-to-noise ratios, make an upset over Luminex unlikely.

Market

We estimate that the worldwide Life Sciences research market in 2008 is in the \$30-40 billion range. Luminex believes that its \$70 million sales in 2006 of *xMAP*-based reagents and kits represented about a 9% penetration of the applicable multiplexing market, implying an overall applicable market of nearly \$800 million in that year. Overall, medical diagnostics accounts for about \$30 billion in worldwide sales, inclusive of \$20 billion in the U.S. The multiplexed immunodiagnostics and HLA-typing portion stood near \$750 million in 2006; *xMAP* reagents and kits may have accounted for \$65 million of that. Estimates of the size of the U.S. molecular diagnostics market in 2008 range from \$2 billion to \$4 billion, growing at about 15% per year. Roughly 350 molecular diagnostic labs are in operation today, but we expect this number to swell over the next five years. CLIA high-complexity labs still perform most molecular diagnostics assays as homebrews; the company's penetration in that sector stands at roughly 1%.

Risks

xMAP is widely used in the research lab, and its penetration into clinical diagnostics is increasing. Luminex's future depends on the continued adherence of assay developers and laboratories to its platform. For immunoassays of protein analytes, the capabilities of the current generation of beads and readers are proven. Increasing the range of multiplexing from 100 to 500 with the *FlexMAP 3D* system may be crucial for research applications involving nucleic acids. Delays in submission of the Device Master File for *FlexMAP 3D* would slow its adoption; other hiccups in the rollout of *FlexMAP 3D* and *MagPlex* beads could also turn development scientists away from Luminex in molecular diagnostics. Similarly, the runaway success of an alternative platform could impact Luminex's market share. The molecular diagnostic market will continue to grow at double-digit paces into the foreseeable future, we believe. However, for fundamental technological reasons, the dynamic range offered by quantitative real-time PCR is much greater than what a bead-based approach can achieve. Thus, despite Q-RT-PCR's disadvantages in ease-of-use and increased risk of cross-contamination, it will gain traction in certain applications over *xMAP*. Luminex has a formidable competitor in Illumina; a sweeping success by *BeadXpress* would come at *xMAP*'s expense.

Luminex

Fiscal Year December 31

Operating & Financial Highlights

(\$ Millions, Adjusted for Certain Items)

	2003	2004	2005	2006	2007	2008F	2009F	2010F
Revenue	26.3	35.9	42.3	53.0	75.0	100.0	138.5	186.0
Operating Income	(5.4)	(3.3)	(2.5)	0.9	(5.0)	0.8	17.6	37.0
Net Income	(3.2)	(2.8)	(1.8)	3.0	(3.5)	1.1	16.2	33.1
Avg Shares Outstanding- Diluted	29.8	30.7	31.0	33.0	34.4	37.4	40.0	41.0
EPS - Diluted	(\$0.11)	(\$0.09)	(\$0.06)	\$0.09	(\$0.10)	\$0.03	\$0.40	\$0.80
Diluted EPS Without FAS 123R				\$0.20	(\$0.00)	\$0.11	\$0.50	\$0.90
<i>Capital Employed</i>								
Property Plant & Equipment	1.7	1.4	3.2	5.0	12.7	5.5	6.0	6.5
Operating Working Capital	2.8	5.7	(1.3)	2.2	2.1	9.0	12.5	17.5
Other / Intangibles	0.9	5.3	6.6	8.6	57.5	10.5	12.0	13.5
total	5.4	12.4	8.6	15.8	72.3	25.0	30.5	37.5
<i>Financing</i>								
Debt	0.0	0.0	0.0	0.0	3.0	0.0	0.0	0.0
Shareholders Equity	44.8	44.5	44.7	54.2	103.5	106.6	125.8	162.9
(Less: Cash)	(39.5)	(32.1)	(36.2)	(38.4)	(34.2)	(81.6)	(95.3)	(125.4)
total	5.4	12.4	8.6	15.8	72.3	25.0	30.5	37.5
<i>Ratios (%)</i>								
Operating Margin	n/a	n/a	n/a	1.7%	n/a	0.8%	12.7%	19.9%
Return on Capital Employed	n/a	n/a	n/a	5.7%	n/a	3.2%	57.7%	98.7%
Return on Tangible Capital	n/a	n/a	n/a	5.7%	n/a	3.2%	57.7%	98.7%
Shareholders Equity / Capital	837.3%	358.8%	522.5%	343.0%	143.2%	426.3%	412.4%	434.3%
<i>Valuation</i>								
Price Earnings Multiple				220.7	n/a	680.0	50.0	25.0
<i>Segment Estimates</i>								
Revenue								
Systems	15.6	19.0	18.8	20.6	23.0	30.0	39.0	52.0
Consumables	6.1	9.0	13.1	15.7	19.0	27.0	33.0	43.0
Reagents/Assays (incl. LMD)	0.0	0.0	0.0	0.0	12.0	17.3	31.0	42.0
Service	1.1	1.6	2.4	3.5	4.5	5.5	7.5	10.0
Other	2.1	3.1	2.7	5.0	6.0	6.0	7.0	8.0
Royalties	1.4	3.2	5.3	8.2	10.5	14.0	21.0	31.0
Misc.	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0
Total	26.3	35.9	42.3	53.0	75.0	100.0	138.5	186.0

Appendix A: Important Disclosures

5.9.2008

Copyright © 2008, GARP Research & Securities Co. All rights reserved.

GARP Research & Securities Co. ("GARP Research") is an independent research firm whose core business is equity research for institutional clients. GARP Research is a dually registered broker dealer & investment adviser, a member organization of FINRA & SIPC, and an accredited member of the Investorside Research Association. GARP Research and its affiliates (Weedflowersm, Inc. and GARP Capital, LLC.) are under common ownership and control. Weedflowersm, Inc., a registered investment advisory firm, manages money in separate accounts. One of these accounts is the Gaineswood Fund, LP. GARP Capital, LLC is the general partner for the Gaineswood Fund, LP.

GARP Research and its affiliates do not make a market or hold positions that exceed 1% in any class of securities of the subject company. Affiliates (including advisory clientele), officers, directors, and employees of GARP Research will from time hold positions in or options on the securities discussed. The table below lists all holdings of GARP-rated stocks by GARP Research analysts and/or their household members. Outside of this disclosed ownership, the analysts are not aware of any other material conflicts of interest.

Analyst Ownership in GARP Recommended Securities	
Analyst	Ownership
Brett Carson	Cosi, ICON, International Rectifier, PPD, Synopsys, Sangamo, Flextronics
Seth Dadds	Ameritrade, Cree, E*Trade, Illumina
Rob Furlong	Analog Devices, Cosi, Flextronics, Sangamo, Taser International
George Sakellaris	Gevity HR, Cree, EW Scripps, International Rectifier, Sangamo, Cosi, Gemstar

GARP Research rates companies as BUY, NEUTRAL, and AVOID (SELL). The rating methodology permits richer valuations when faster rates of earnings growth are expected (see "Ratings Matrix" table below). BUY rated stocks have a combined "Growth Score" and "Value Score" of less than six, NEUTRAL between six and nine, and AVOID rated stocks nine or more. Another important consideration in determining the rating is whether the underlying company possesses characteristics consistent with the investment philosophy of GARP Research. This includes an assessment of quality (through competitive analysis and current or projected return on invested capital) and control of risk (determined by technical and quantitative factors). Ratings may also take into account growth beyond terminus years. The percentage of BUY, NEUTRAL, and SELL ratings was recently 69%, 30%, and 1%, respectively. The percentage of BUY, NEUTRAL, and SELL for subject companies for whom GARP Research has provided investment banking services in the past 12 months is 0%. GARP Research and its affiliates do not conduct corporate finance activities. Past performance is not indicative of future results.

Ratings Matrix			
Earnings Growth*	Growth Score	Out-Year P/E**	Value Score
>17%	1	<10x	1
14-17%	2	10-12x	2
12-14%	3	12-14x	3
9-12%	4	14-16x	4
<9%	5	>16x	5

*Annualized earnings growth over a two to four year time horizon.
 **Out-year P/E is determined by the current price divided by our diluted EPS estimate two- to four-years forward.

The information contained herein has been obtained from sources believed reliable but is not necessarily complete and accuracy is not guaranteed. Opinions expressed are subject to change without notice and do not constitute solicitation of orders.

Additional information is available upon request at (410) 764-1300.



The Investorside Research Association certifies its members have no investment banking conflicts.


Analyst Certification

All of the views expressed in the report accurately reflect the personal views of the research analyst about any and all of the subject companies. No part of the compensation of the research analyst named herein was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by the research analyst in this report. Neither the research analyst nor a member of the analyst's household serves as an officer, director or advisory board member of any company mentioned in the report.

-Alastair Mackay

LUMINEX CORP, Daily

May 09, 2008



Source: Bloomberg L.P.

INVESTMENT RESEARCH & INSTITUTIONAL SALES

Brett Carson, CFA	carson@garpresearch.com	410-318-5031
Seth Dadds	dadds@garpresearch.com	410-318-5021
Robert Furlong, CFA	furlong@garpresearch.com	410-318-5015
Alistair Mackay, Ph.D.	mackay@garpresearch.com	410-318-5022
Seth Moshman, CPA	moshman@garpresearch.com	410-318-5017
George Sakellaris, CFA	sakellaris@garpresearch.com	410-318-5016

PUBLICATIONS

More information about our firm, our coverage our research and our performance history can be found on our website, or by typing **GRCO <Go>** on **Bloomberg**.

Entitled clients can access our research on **Thomson, Reuters, Bloomberg, Capital IQ, Factset** and **Zacks Investment Research**. Please contact us should you need proper entitlement for access.

INSTITUTIONAL EQUITY TRADING INSTRUCTIONS

GARP Research, Inc., a FINRA-registered broker dealer and a member of the SIPC. We offer several ways to facilitate the payment of our investment research services.

Commission Sharing Agreements:

GARP Research has Commission Sharing Agreements (CSA's) with **Lehman Brothers, Citigroup, Goldman Sachs, BayPoint Trading (BTIG)** and **Instinet**. Institutional clients can place orders through their normal trading contacts at these firms and direct commission dollars to our firm in payment for our research services.

Our primary contact(s) at Lehman Brothers are:

Chris Caras Vice President 212-526-9490 chcaras@lehman.com	Kevin Petrello SVP-Head of US Commission Management 212-526-9459 kpetrell@lehman.com
---	--

If you have any questions, please call Seth Moshman.